Literature DB >> 23328521

Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease.

Magnus P Ekström1, Anna Bornefalk Hermansson, Kerstin E Ström.   

Abstract

RATIONALE: Cardiovascular drugs may improve survival in chronic obstructive pulmonary disease (COPD). However, previous studies did not account for major sources of bias, and drug effects have not been evaluated in severe COPD.
OBJECTIVES: To estimate the time-dependent effects of cardiovascular drugs on survival in oxygen-dependent COPD, accounting for immortal and immeasurable time bias.
METHODS: Prospective national study of patients starting long-term oxygen therapy for COPD in Sweden between 1 October 2005 and 30 June 2009. Effects on mortality were estimated using extended Cox regression adjusted for age, sex, PaO2, PaCO2, World Health Organization performance status, body mass index, comorbidity, and concomitant medications. Immortal and immeasurable time bias was addressed by analyzing all medications as time-dependent variables and accounting for hospitalized time, respectively.
MEASUREMENTS AND MAIN RESULTS: Time-dependent effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, antiplatelet drugs, β-blockers, and statins on all-cause mortality were measured. Of the 2,249 included patients, 1,129 (50%) died under observation. No patient was lost to follow-up. The adjusted time-dependent model was compatible with reduced mortality for antiplatelet drugs (hazard ratio [HR], 0.86; 95% CI, 0.75-0.99; P = 0.030) and trends for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (HR, 0.90; 95% CI, 0.79-1.04; P = 0.166) and statins (HR, 0.86; 95% CI, 0.72-1.03; P = 0.105), whereas β-blockers increased mortality (HR, 1.19; 95% CI, 1.04-1.37; P = 0.010).
CONCLUSIONS: This study supports that antiplatelet drugs improve survival and β-blockers decrease survival in oxygen-dependent COPD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328521     DOI: 10.1164/rccm.201208-1565OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

1.  A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Maria E Laucho-Contreras; Hans Petersen; Vanesa Bijol; Lynette M Sholl; Mary E Choi; Miguel Divo; Victor Pinto-Plata; Alfredo Chetta; Yohannes Tesfaigzi; Bartolomé R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

Review 2.  Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.

Authors:  Mario Cazzola; Luigino Calzetta; Barbara Rinaldi; Clive Page; Giuseppe Rosano; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPD.

Authors:  Tadahiro Goto; Yuichi J Shimada; Mohammad Kamal Faridi; Carlos A Camargo; Kohei Hasegawa
Journal:  J Gen Intern Med       Date:  2018-06-08       Impact factor: 5.128

Review 4.  Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.

Authors:  Vasiliki Petta; Fotis Perlikos; Stelios Loukides; Petros Bakakos; Athanasios Chalkias; Nicoletta Iacovidou; Theodoros Xanthos; Dorothea Tsekoura; Georgios Hillas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 5.  Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Authors:  Alvar Agustí; Peter M Calverley; Marc Decramer; Robert A Stockley; Jadwiga A Wedzicha
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 6.  Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction.

Authors:  Abhishek Jaiswal; Astha Chichra; Vinh Q Nguyen; Taraka V Gadiraju; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2016-02

Review 7.  The pharmacological approach to the elderly COPD patient.

Authors:  Timothy E Albertson; Michael Schivo; Amir A Zeki; Samuel Louie; Mark E Sutter; Mark Avdalovic; Andrew L Chan
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

8.  β-Blockers are associated with a reduction in COPD exacerbations.

Authors:  Surya P Bhatt; James M Wells; Gregory L Kinney; George R Washko; Matthew Budoff; Young-Il Kim; William C Bailey; Hrudaya Nath; John E Hokanson; Edwin K Silverman; James Crapo; Mark T Dransfield
Journal:  Thorax       Date:  2015-08-17       Impact factor: 9.139

9.  Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study.

Authors:  Yaa-Hui Dong; Chia-Hsuin Chang; Li-Chiu Wu; Mei-Shu Lai
Journal:  Eur J Clin Pharmacol       Date:  2016-07-22       Impact factor: 2.953

Review 10.  Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

Authors:  Daniela Castiglia; Salvatore Battaglia; Alida Benfante; Claudio Sorino; Nicola Scichilone
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.